With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.
The company reported total revenues of $384.9 million, up from $375.4 million for the first quarter of 2016 and above analysts' consensus estimate of $372.7 million.
Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.
The company reported revenues of $470.3 million, down from $478.2 million in Q4 2015 but beating the average analysts' estimate of $464.5 million.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.